# Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

> **NCT01792700** · PHASE4 · COMPLETED · sponsor: **Seoul National University Bundang Hospital** · enrollment: 648 (actual)

## Conditions studied

- Helicobacter Infections

## Interventions

- **DRUG:** esomeprazole
- **DRUG:** tripotassium dicitrate bismuthate
- **DRUG:** metronidazole
- **DRUG:** tetracycline
- **DRUG:** moxifloxacin
- **DRUG:** amoxicillin

## Key facts

- **NCT ID:** NCT01792700
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 648 (ACTUAL)
- **Last updated:** 2013-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01792700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01792700, "Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT01792700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*